Apricot Health

Generative AI drafting the documentation is the product. There is no electronic medical record, no services business and no prior software underneath it, and the company describes itself as AI native. What it automates is the drafting of OASIS and visit documentation from captured content, which is the model doing the work rather than a workflow layer presenting someone else's output.

The oversight advantage here is architectural rather than procedural, which is the strongest kind. Because documentation is drafted from a GUIDED INTERVIEW the clinician completes after the visit, plus structured capture during it, the clinician supplies the content rather than a model inferring it from overheard conversation. That materially narrows the fabrication surface compared with ambient generation, and the company argues the point explicitly, positioning against approaches it characterises as riskier. An in home visit guide reduces omission during capture, and the company's own representatives state plainly that the product drafts OASIS forms from patient documents but does not replace clinical decisions, with agency review keeping final decisions with the team. Held at B because none of it is quantified: no accuracy or error rate, no confidence signal, no abstention behaviour when the interview leaves a required field unsupported, and no statement of what the agency review layer actually catches.

The company names transparent reasoning as a product property, meaning a clinician can see why a recommendation or draft entry was produced rather than receiving it unexplained. That is a real feature claim and more than several competitors offer. Nothing else is disclosed: no model or model family named, no accuracy figure for OASIS field completion or narrative generation, no evaluation methodology, no error taxonomy and no model card. For a product whose output is a regulated assessment instrument, per field accuracy is the disclosure that matters and none exists publicly.

Strong commercial signals, no measured customer outcome. A Series A led exclusively by Insight Partners in October 2025, that firm's first investment in an Oklahoma company, is meaningful external diligence, and a co branded integration page on the Netsmart marketplace is a documented partnership rather than an assertion. Against that, no customer is named anywhere, described only as ranging from regional operators to national leaders, and no case study, controlled comparison or independent evaluation exists. The headline figure needs reading carefully: Start of Care documentation falling from 120 minutes to 15 to 30 minutes is footnoted as being measured against leading EMR TIME TARGETS rather than against observed time at a customer. A target is not a baseline, and comparing measured performance to somebody's target overstates the delta by whatever gap already existed between target and reality. Ask for before and after timings at a named agency.

No retention period, training use statement or de identification posture was located. Not Rated reflects absent retrieval. The capture surface makes the questions specific and worth asking directly: the product records in home time, consents, vital signs, assessments, PHOTOGRAPHS and targeted audio inside a patient's home, which is a broader and more intimate data set than a clinic based product collects. Establish what happens to the photographs and the audio in particular, how long each is held, and whether either is used to improve models.

No HIPAA compliance statement and no business associate agreement terms were located on any retrieved surface. A BAA plainly exists given deployment at home health agencies and integration with a major post acute record, but the index grades what is disclosed and nothing is.

No SOC 2, HITRUST, ISO 27001 or other attestation was located, and no trust centre or security page was found. Not Rated reflects absent retrieval. Worth requesting given the product captures photographs and audio inside patients' homes on mobile devices, which is a different exposure profile from a desktop application inside a facility.

No FDA clearance or device authorisation was located and none is expected, since the product completes a documentation and assessment instrument rather than making a diagnosis. The regulatory exposure that does matter sits in the CMS conditions of participation for home health and in the accuracy of the OASIS assessment itself, which drives both quality reporting and payment. Ask how the vendor supports an agency through an OASIS accuracy audit, since that is the regulatory event this product's output would be examined in.

The grade describes incentive structure and disclosure, and the counterweights are substantial and belong first. The company states that clinician informed recommendations keep coding and documentation aligned while transparent reasoning and agency review leave every final decision with the team, its representatives state directly that it does not replace clinical decisions, the founder ran a home health agency for seven years, and the design is described as informed by extensive field research with nurses. The founder has also publicly convened discussion on how agencies should vet AI vendors before letting them touch clinical documentation, which is an unusual thing for a vendor to organise. Against that, OASIS is not a neutral form: it drives case mix under the Patient Driven Groupings Model, so a product that shapes OASIS responses is operating on the instrument that determines what a thirty day episode pays. That places it on the same payment unit as Andy AI, and it is the reason this sits at C rather than higher. No fairness, subgroup or demographic performance disclosure was located.

One integration is properly evidenced rather than merely claimed, which is worth more than a long unnamed list. Apricot integrates with Netsmart myUnity, the post acute care record, and appears on the Netsmart marketplace with a co branded page authored jointly with that vendor. Being carried in a post acute EMR's own catalogue is a form of external validation, since the platform vendor applies its own review before listing, and it also tells a buyer the integration is supported rather than improvised. The product is separately demonstrated for Axxess users. Held at B because Netsmart is the only integration described in any depth, the remaining post acute record systems that dominate this segment are not addressed, and no integration mechanism or standard is described.

No hosting model, cloud provider, region or residency commitment was located. Not Rated reflects absent retrieval. One aspect deserves a question beyond the usual: the product is used in patients' homes where connectivity is frequently poor, so establish whether capture works offline and where content is held on the device until it syncs, which is both an operational and a security question.

No price, tier or pricing mechanism was located on any retrieved surface. Not Rated is the house convention for absent pricing rather than a low grade. Worth checking the Netsmart marketplace listing during evaluation, since partner catalogues occasionally carry pricing or packaging detail a vendor's own site omits.

Narrow by design and deep within the narrow part. The product addresses home health and post acute care, and within that it began with the Start of Care visit, the most complex and time consuming documentation event in the segment, covering it end to end across medication reconciliation, wound documentation, calendar plotting, interventions and goals and narratives. That is instrument level work rather than generic summarisation, since OASIS is a specific regulated assessment. Support is described as extending to other OASIS, therapy and routine visits. Graded B rather than A because the breadth beyond Start of Care is recent or announced rather than demonstrated, and because coverage does not extend past this one care setting.